Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaoru Tsuchiya

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
Clinical Case Reports|July 7, 2023
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling testShun Ishido, Nobuharu Tamaki, Kento Inada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2021
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin gradeShun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Cancers|June 24, 2022
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter StudyYutaka Yasui, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Journal of Clinical Medicine|December 11, 2025
Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific ThresholdsShohei Kimura, Nobuharu Tamaki, Mayu Higuchi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2026
Lactulose and rifaximin combination therapy as first-line treatment for preventing recurrent overt hepatic encephalopathy: a retrospective observational studyYuki Tanaka, Nobuharu Tamaki, Hiroyuki Nakanishi, et al.
Internal Medicine (Tokyo, Japan)|September 7, 2022
Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic EncephalopathyYuka Hayakawa, Nobuharu Tamaki, Hiroyuki Nakanishi, et al.
Journal of Gastroenterology and Hepatology|January 25, 2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analogSakura Kirino, Nobuharu Tamaki, Shun Kaneko, et al.
Liver Cancer|October 30, 2023
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept StudyMasatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Nutrients|May 13, 2026
Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver CirrhosisYuki Tanaka, Nobuharu Tamaki, Hiroyuki Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 19, 2022
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis BSakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
Clinical Case Reports|July 7, 2023
Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling testShun Ishido, Nobuharu Tamaki, Kento Inada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2021
Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin gradeShun Kaneko, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Cancers|June 24, 2022
Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter StudyYutaka Yasui, Masayuki Kurosaki, Kaoru Tsuchiya, et al.
Journal of Clinical Medicine|December 11, 2025
Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific ThresholdsShohei Kimura, Nobuharu Tamaki, Mayu Higuchi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2026
Lactulose and rifaximin combination therapy as first-line treatment for preventing recurrent overt hepatic encephalopathy: a retrospective observational studyYuki Tanaka, Nobuharu Tamaki, Hiroyuki Nakanishi, et al.
Internal Medicine (Tokyo, Japan)|September 7, 2022
Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic EncephalopathyYuka Hayakawa, Nobuharu Tamaki, Hiroyuki Nakanishi, et al.
Journal of Gastroenterology and Hepatology|January 25, 2020
Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analogSakura Kirino, Nobuharu Tamaki, Shun Kaneko, et al.
Liver Cancer|October 30, 2023
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept StudyMasatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Nutrients|May 13, 2026
Serum Zinc Threshold and the Prognostic Impact of Zinc Supplementation in Liver CirrhosisYuki Tanaka, Nobuharu Tamaki, Hiroyuki Nakanishi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 19, 2022
Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analog therapy in patient with chronic hepatitis BSakura Kirino, Nobuharu Tamaki, Masayuki Kurosaki, et al.
Pageof 15